IP and Startup Valuation in Times of Crisis
Tuesday, August 25 , 2020
1:00 pm - 2:00 pm Eastern Time 12:00 pm - 1:00 pm Central Time
11:00 am- 12:00 pm Mountain Time 10:00 am - 11:00 am Pacific Time
Intellectual property (IP) accounts for a significant portion of the corporate value of Biotech, Pharmaceutical and Medical Device companies, particularly in the early, pre-revenue stage. It is the main asset by which startups leverage funding, generate revenues or manage to secure a successful exit. That being said, the recent COVID-19 pandemic has heightened some of the frictions surrounding IP and technology monetization rights, particularly when it comes to inventions resulting from federally-funded R&D. This webinar will explore the critical relationship between IP and valuation in the life sciences sector, while focusing on the unique role IP plays in startup funding and exits (M&A or IPO). Through case studies and industry metrics, we will explore some of the key IP valuation models, how they are impacted by recent events (such as the COVD-19 epidemic), and what can be done to optimize valuation and return on investment in times of crisis.
Key learnings objectives include: - Trends in early stage life-sciences company valuations and exits. - The correlation between life-science company valuations and their IP positions. - The impact of IP position on startup valuations: lessons learned from the Unicorns - Recent IP developments related to COVID-19 and their potential impact on technology transfer, IP valuation and startup funding and exits in the life sciences sector.
Efrat Kasznik , Foresight Valuation Group
Efrat Kasznik is President of Foresight Valuation Group and a Lecturer at the Stanford Graduate School of Business. Efrat is a Silicon-Valley based valuation and intellectual property expert with two decades of consulting experience, focusing on assisting IP holders across industries with the valuation and monetization of their intangible assets. She helps clients, ranging in size from Fortune 100 companies to start-ups, with IP and business valuations in support of licensing deals, IP and technology acquisitions, M&A transactions, tax reporting, strategic planning, and fundraising. She also frequently serves as a testifying expert in legal disputes involving IP and startup valuations and damages. Efrat is the immediate past-Chair of the High-Tech Sector, LES USA/Canada, and has been recognized as a top IP strategist on the IAM 300 list every year since 2013.
LES Members Price: FREE
(LESI Members please contact firstname.lastname@example.org for a code) Non-Members: $69
Want to view this and all LES webinars (recorded and LIVE) for free Join LES Today!
By registering for this event, you permit LES to use your email address to communicate with you regarding LES events and their other services. You will have the ability to unsubscribe from these communications going forward.